DePuy Synthes

Company

Last mentioned: Mar 12, 2026

Timeline

  1. BofA Price Target Hike

    Bank of America increases price target, highlighting R&D productivity and MedTech growth.

  2. Fast-Track Approval

    USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.

  3. 12-Month High

    JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.

Stories mentioning DePuy Synthes 1

pharma Neutral

BofA Bullish on Johnson & Johnson as Pipeline Momentum Accelerates

Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.

2 sources